Albuquerque neuroscience Inc

Albuquerque, New Mexico 87109

0 studies enrolling now · 44 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder, Attention Deficit/Hyperactivity Disorder, Attention-Deficit/Hyperactivity Disorder, Attention-deficit/Hyperactivity Disorder, Bipolar Depression, Dementia, Depression, Depressive Disorder, Major, Diabetes Mellitus, Early Alzheimer's Disease

Studies at this site

• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) — Completed
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) — Completed
• A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder. — Completed
• A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) — Running, not enrolling
• Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease — Completed
• HbA1c Variation Study — Completed
• Open-label Extension for Phase 3 Clinical Trials of Simufilam — Stopped early
• A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication — Completed
• Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults — Completed
• Randomized Trial of Adult Participants With Generalized Anxiety Disorder — Completed
• Software Treatment for Actively Reducing Severity of ADHD in Adolescents (STARS-ADHD-Adolescents) — Completed
• Software Treatment for Actively Reducing Severity of ADHD in Adults (STARS ADHD Adult) — Completed
• Safety and Efficacy in Adult Subjects With Acute Migraines — Completed
• Open Label Safety Study in Acute Treatment of Migraine — Completed
• Fasudil fOr redUcing elopemeNt and Spatial Disorientation — Completed
• AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext — Completed
• Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl — Completed
• FreeStyle Libre Flash Glucose Monitoring System Post Approval Study — Completed
• SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study — Stopped early
• Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder — Completed
• SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder — Completed
• FreeStyle Libre Flash Glucose Monitoring System Post Approval Study for Pediatric Patients — Stopped early
• Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) — Stopped early
• Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder — Completed
• A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia — Stopped early
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03) — Completed
• ELND005 in Patients With Mild to Moderate Alzheimer's Disease — Completed
• ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease — Completed
• An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine — Completed
• Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine — Completed
• Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM — Completed
• A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy — Completed
• Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression — Completed
• Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression — Completed
• Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Stopped early
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) — Completed
• A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression — Completed
• A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia. — Completed
• Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia — Completed
• Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder — Completed
• ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301) — Completed